782 related articles for article (PubMed ID: 15207427)
1. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
2. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
4. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
5. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
6. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
[TBL] [Abstract][Full Text] [Related]
9. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Crowell TA; Paramadevan J; Abdullah L; Mullan M
J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
Wattmo C; Wallin ÅK; Londos E; Minthon L
Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
[TBL] [Abstract][Full Text] [Related]
13. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
15. Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy.
Rozzini L; Vicini Chilovi B; Bellelli G; Bertoletti E; Trabucchi M; Padovani A
Int J Geriatr Psychiatry; 2005 Jun; 20(6):547-51. PubMed ID: 15920713
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
18. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
19. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
